The Pancreatic Islet Transplant Rejection drugs in development market research report provides comprehensive information on the therapeutics under development for Pancreatic Islet Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pancreatic Islet Transplant Rejection. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pancreatic Islet Transplant Rejection and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Pancreatic Islet Transplant Rejection by eight companies/universities/institutes. The top development phase for Pancreatic Islet Transplant Rejection is preclinical with three drugs in that stage. The Pancreatic Islet Transplant Rejection pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Pancreatic Islet Transplant Rejection pipeline products market are: University of Wisconsin Madison, Dompe Farmaceutici and TikoMed.
The key targets in the Pancreatic Islet Transplant Rejection pipeline products market include Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12), Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40), and Nuclear Receptor Subfamily 1 Group I.
The key mechanisms of action in the Pancreatic Islet Transplant Rejection pipeline product include Erythropoietin Receptor (EPOR) Agonist with one drug in Phase I. The Pancreatic Islet Transplant Rejection pipeline products include four routes of administration with the top ROA being Intravenous and five key molecule types in the Pancreatic Islet Transplant Rejection pipeline products market including Small Molecule, and Synthetic Peptide.
Pancreatic Islet Transplant Rejection overview
Pancreatic Islet Transplant Rejection is a process in which a transplant recipient’s immune system attacks the transplanted Pancreatic Islets. Various mechanisms involving chronic inflammation, humoral, and cellular immune reactions play essential roles in the immunopathogenesis of rejections
For a complete picture of Pancreatic Islet Transplant Rejection’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
